Mean platelet volume is associated with myocardial perfusion defect in diabetic patients

Savas Sarikaya, Safak Sahin, Lutfi Akyol, Elif Borekci, Yunus Keser Yilmaz, Fatih Altunkas, Kayihan Karaman, Seyhan Karacavus, Ali Riza Erbay

Abstract

Aim: Our aim was to evaluate whether there was a relationship between mean platelet volume and myocardial perfusion defect in diabetic patients using myocardial perfusion imaging.

Method: Forty-four diabetic patients with myocardial perfusion defect (group 1) and 44 diabetic patients without myocardial perfusion defect (group 2), matched for age and gender, were retrospectively examined. Levels of mean platelet volume (MPV) in the two groups were assessed.

Results: MPV was higher in group 1 than group 2 patients (8.76 ± 0.76 and 8.25 ± 0.78 fl), respectively, \( p = 0.003 \). Levels of glucose, triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, haemoglobin (Hb) and glycosylated haemoglobin (HbA1c), and body mass index (BMI) in the two groups were not statistically significantly different. Multivariate logistic regression analyses showed that MPV was the only variable independently associated with myocardial perfusion defects (OR: 2.401, 95% CI: 1.298–4.440, \( p = 0.013 \)).

Conclusion: This study showed that higher MPV was associated with myocardial perfusion defects. Higher MPV in diabetic patients was independently related to myocardial perfusion defects and may be an indicator of myocardial ischaemia.

Keywords: myocardial perfusion defect, mean platelet volume, diabetes mellitus

Submitted 18/7/13, accepted 14/3/14
Cardiovasc J Afr 2014; 25: 110–113 www.cvja.co.za
DOI: 10.5830/CVJA-2014-013

Diabetes mellitus (DM) is considered a coronary artery risk equivalent. DM is associated with an increased risk of cardiovascular morbidity and mortality. DM may cause myocardial perfusion defects involving the main coronary artery and myocardial microvascular circulation. Myocardial perfusion imaging (MPI) is a useful non-invasive tool to determine whether there is a myocardial perfusion defect.

Platelet volume is a marker of platelet activation and function and is measured as mean platelet volume (MPV). MPV has become a prognostic factor in coronary heart disease and may eventually be accepted as a parameter of platelet activity. MPV is emerging as a new risk factor for vascular complications of DM of which atherothrombosis plays a crucial role.

However, to the best of our knowledge, there have been no reports in the literature to evaluate the relationship between MPV and myocardial perfusion defect using MPI in patients with diabetes. Our aim was to evaluate whether there was a relationship between myocardial perfusion defect using myocardial perfusion scintigraphy and MPV in selected diabetic patients.

Methods

Eighty-eight patients with type 2 diabetes who had MPI between January and May 2013 in Bozok and Gaziosmanpaşa universities were retrospectively examined. Eighty-eight patients were enrolled in the study and divided into two groups, matched for age and gender: the myocardial perfusion defect group (group 1) and a group with no myocardial perfusion defect (group 2). Group 1 consisted of 44 subjects (14 men and 30 women, mean age: 61.75 ± 7.86 years). Group 2 consisted of 44 subjects (12 men and 32 women, mean age: 60.48 ± 9.28 years).

Patients with a history of myocardial infarction, unstable angina pectoris, cardiac surgery, angiographically proven coronary artery disease, endocrine disorder without diabetes, systemic inflammatory disease, rhythm disorder, any medication that could affect the MPV, suspicious scintigraphy results due to breast attenuation, and aperture and fixed (scar) perfusion defects were excluded.

The blood samples were withdrawn following a 12-hour fast. Glucose, creatinine and lipid profiles were determined using standard methods. For both groups, we measured the MPV from blood samples that were obtained following venipuncture. The
blood was collected in tripotassium EDTA tubes. We analysed the blood samples using an automatic blood counter within one hour of drawing the blood.

The patients underwent a two-day stress/rest single-photon-emission tomography and gated GSPECT study using adenosine with a standard weight-based infusion protocol (140 μg/kg/min). The six-minute adenosine infusion was begun and 740 MBq (20 mCi) of MIBI was injected after three minutes. After a 45-minute delay, a stress set of images was acquired.

At rest, before receiving technetium-99m methoxy isobutyl isonitrile (99mTc-MIBI), the patients were given one to two tablets of sublingual nitroglycerin (0.4 mg), five minutes apart and they were injected with 740 MBq (20 mCi) of MIBI. A GSPECT study was performed 45 minutes later.

GSPECT data were acquired in the supine position with the double-head SPECT-γ camera equipped with a high-resolution low-energy collimator. The obtained data were projected as myocardial tomographic slices in short-axis, vertical long-axis and horizontal long-axis views. Electrocardiogram gating was applied to the cardiac cycle with eight frames per cardiac cycle. The myocardium was divided into 17 segments following the American Society of Nuclear Cardiology/American College of Cardiology/American Heart Association guidelines.9

GSPECT dates were processed and analysed using 4D-MSPECT software, which determines the extent and severity of left ventricular perfusion defect size and the extent of reversible (ischaemia) or fixed (scar) perfusion defects. The programme assigned a score of 0 to 4 to each segment based on activity level: 0 = normal, 1 = equivocal, 2 = moderate, 3 = severe reduction of radioisotope uptake, and 4 = absence of detectable tracer uptake. Abnormal perfusion, motion and thickening were defined as a score of ≥2.

The summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) were calculated based on the conventional 17-segment model. The summed difference score (SDS), indicating the extent of reversible perfusion defects, was obtained by calculating the differences between the SSS and SRS.

**Statistical analysis**

Statistical analyses were performed using SPSS 18.0 software. Parametric values are given as mean ± standard deviation and non-parametric values as a percentage. To compare parametric continuous variables, the Student’s t-test was used; to compare non-parametric continuous variables, the Mann–Whitney U-test was used. Categorical data were compared by chi-square distribution. Stepwise multivariate logistic regression models were created to determine independent variables for myocardial perfusion defect. For multivariate regression, variables with a p-value < 0.1 in univariate analysis were selected. Two-tailed p-values < 0.05 were considered to indicate statistical significance.

**Results**

Baseline characteristic of the patients are given in Table 1. Levels of glucose, triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, haemoglobin (Hb) and glycosylated haemoglobin (HbA1c) and body mass index (BMI) in the two groups were not statistically significantly different. The MPV level was higher in group 1 than in group 2 patients (8.76 ± 0.78 and 8.25 ± 0.78 fl, respectively, p = 0.003). Levels of MPV in the two groups are shown in Fig. 1.

Univariate analysis showed that MPV, and HbA1c and glucose levels were significantly involved in myocardial perfusion defects. Multivariate logistic regression analyses showed that MPV was the only variable independently associated with myocardial perfusion defect (OR: 2.401, 95% CI: 1.298–4.440, p = 0.013) (Table 2).

**Discussion**

This study showed that there was a relationship between myocardial perfusion defect and MPV. MPV was higher in the group with myocardial perfusion defects, compared to the one without myocardial perfusion defects. Patients with diabetes develop vascular complications, including macrovascular complications [coronary artery disease (CAD), peripheral vascular disease and stroke] and microvascular complications [diabetic nephropathy (DN), diabetic retinopathy (DR) and

| Table 1. Baseline characteristic of the patients. |
|-------------------------------------------------|
| **Groups**                                      |
| Age (years)                                     |
| Group 1  | 60.02 ± 9.28                      | 60.81 ± 8.02                      | 0.660  |
| Group 2  | 60.81 ± 8.02                      | 60.81 ± 8.02                      | 0.660  |
| Women (%)                                       |
| Group 1  | 72.7                               | 68.2                               | 0.408  |
| Group 2  | 72.7                               | 86.4                               | 0.093  |
| HT (%)                                          |
| Group 1  | 72.7                               | 86.4                               | 0.093  |
| Group 2  | 72.7                               | 86.4                               | 0.093  |
| HL (%)                                          |
| Group 1  | 47.7                               | 56.8                               | 0.281  |
| Group 2  | 47.7                               | 56.8                               | 0.281  |
| Aspirin (%)                                     |
| Group 1  | 34.1                               | 29.5                               | 0.410  |
| Group 2  | 34.1                               | 29.5                               | 0.410  |
| BMI (kg/m²)                                     |
| Group 1  | 31.41 ± 6.23                      | 30.41 ± 5.7                        | 0.446  |
| Group 2  | 31.41 ± 6.23                      | 30.41 ± 5.7                        | 0.446  |
| Glucose (mg/dl)                                 |
| Group 1  | 131.79 ± 40.553                   | 151.16 ± 54.213                   | 0.070  |
| Group 2  | 131.79 ± 40.553                   | 151.16 ± 54.213                   | 0.070  |
| TG (mg/dl)                                      |
| Group 1  | 192.36 ± 116.48                   | 171.71 ± 87.321                   | 0.600  |
| Group 2  | 192.36 ± 116.48                   | 171.71 ± 87.321                   | 0.600  |
| TC (mg/dl)                                      |
| Group 1  | 190.04 ± 42.25                    | 178.83 ± 46.73                    | 0.258  |
| Group 2  | 190.04 ± 42.25                    | 178.83 ± 46.73                    | 0.258  |
| HDL-C (mg/dl)                                   |
| Group 1  | 40.58 ± 5.911                     | 38.68 ± 6.08                      | 0.167  |
| Group 2  | 40.58 ± 5.911                     | 38.68 ± 6.08                      | 0.167  |
| LDL-C (mg/dl)                                   |
| Group 1  | 118.77 ± 28.75                    | 108.28 ± 33.82                    | 0.133  |
| Group 2  | 118.77 ± 28.75                    | 108.28 ± 33.82                    | 0.133  |
| Hb (g/dl)                                       |
| Group 1  | 13.16 ± 1.40                      | 13.42 ± 1.46                      | 0.399  |
| Group 2  | 13.16 ± 1.40                      | 13.42 ± 1.46                      | 0.399  |
| MPV (fl)                                        |
| Group 1  | 8.76 ± 0.76                       | 8.25 ± 0.78                       | 0.003  |
| Group 2  | 8.76 ± 0.76                       | 8.25 ± 0.78                       | 0.003  |
| HbA1c (%)                                       |
| Group 1  | 8.67 ± 0.68                       | 8.35 ± 0.86                       | 0.094  |
| Group 2  | 8.67 ± 0.68                       | 8.35 ± 0.86                       | 0.094  |

HT: hypertension; HL: hyperlipidaemia; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Hb: haemoglobin; MPV: mean platelet volume; HbA1c: glycosylated haemoglobin.
**Table 2. Univariate and multivariate regression analyses of independent variables for MPD.**

| Variables | Univariate | Multivariate |
|-----------|------------|--------------|
|           | OR 95% CI p-value | OR 95% CI p-value |
| MPV (fl)  | 2.401 (1.298–4.440) 0.005 | 2.484 (1.215–5.081) 0.013 |
| Glucose (mg/dl) | 1.009 (0.999–1.029) 0.072 | 1.008 (0.997–1.019) 0.178 |
| HbA1c (%) | 1.800 (0.993–3.474) 0.08 | 1.984 (0.980–4.018) 0.064 |
| Age (years) | 1.244 (0.497–3.16) 0.646 | |  
| HT (mg/dl) | 2.375 (0.801–7.043) 0.119 | |  
| BMI (kg/m²) | 0.991 (0.92–1.067) 0.820 | |  
| TC (mg/dl) | 0.994 (0.984–1.004) 0.256 | |  
| TG (mg/dl) | 0.998 (0.994–1.002) 0.360 | |  
| HDL-C (mg/dl) | 0.948 (0.878–1.023) 0.256 | |  
| LDL-C (mg/dl) | 0.989 (0.975–1.003) 0.134 | |  
| Hb (%) | 1.138 (0.845–1.534) 0.395 | |  

Continuous hyperglycaemia may cause endothelial dysfunction and vascular lesions, resulting in diabetic vascular complications.11,12

Type 2 diabetes is a substantial risk factor in atherosclerotic cardiovascular disease.9,10 Cardiovascular disease (CVD) is the leading cause of death in patients with type 2 DM.11 Asymptomatic CAD is common in patients with DM and is a strong predictor of future poor outcome of coronary vascular events, as well as early death.10,11,12 DM is associated with generalised endothelial dysfunction and small-vessel abnormalities.10,11

Perfusion defects are substantial predictors of coronary events in patients with known or suspected coronary heart disease (CHD).10,11,12,13,14 It is proposed that concomitant abnormalities of perfusion imaging scans in patients with diabetes with normal coronary angiograms may be caused by micro-angiopathy or endothelial dysfunction. Accordingly, it reflects an increased likelihood of future coronary events.10,11,12,13

The majority of studies on ischaemia have used SPECT MPI. An analysis of the diagnostic accuracy of pharmacologically induced stress MPI reported a mean sensitivity and specificity of 88 and 77%, respectively.22

Platelet volume is a marker of platelet activation and function, and is measured using MPV. Platelets that have dense granules are more active biochemically, functionally and metabolically. Large platelets secrete high levels of prothrombinogenic thromboxone A2, serotonin, beta-thromboglobulin and procoagulant membrane proteins such as P-selectin and glycoprotein IIb.23 Platelets secrete a large number of substances that are crucial mediators of coagulation, inflammation, thrombosis and atherosclerosis.24,25 It is also well known that large platelets are a risk factor for developing coronary thrombosis, leading to myocardial infarction.26,27

Measurement of platelet activation and/or aggregation may provide prognostic information in patients at risk for or following a cardiovascular event.28,29 Reports have revealed that there is a close relationship between MPV and cardiovascular risk factors, including impaired fasting glucose levels, diabetes mellitus, hypertension, hypercholesterolaemia, obesity and the metabolic syndrome.30,31 Increased platelet activity is reported to play a role in the development of vascular complications in diabetic patients.18

MPV was increased in patients with SCF complex and cardiac syndrome X, both being related to microvascular defects and endothelial dysfunction.32,33 In the present study, we showed that MPV was associated with myocardial perfusion defect, using MPI in diabetic patients.

In our study, MPV was increased in the myocardial perfusion defect group compared to those without myocardial perfusion defects. DM not only involves the main coronary artery but also the microvascular circulation, leading to myocardial perfusion defects. Perfusion defects are significant predictors of coronary events in patients with known or suspected CHD.34

The main limitation of our study was the small sample size, which could result in low statistical power for equivalency testing, leading to false-negative results. Second, because of the retrospective nature of data collection, the angiographic results of the patients were not evaluated. MPI may reflect myocardial perfusion defects but it was not able to show the anatomical status of the coronary artery. We cannot extend our results to the general population due to our broad exclusion criteria.

**Conclusion**

MPV levels were higher in the diabetic patients with myocardial perfusion defects than in those without myocardial perfusion defects. In diabetic patients, increased MPV may be an independent marker of myocardial perfusion defects, which are associated with adverse coronary events.

**References**

1. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? results from 25 years of follow-up in the Renfrew and Paisley survey. *Diabetes Care* 2005; 28: 1588–1593.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *J Am Med Assoc* 1979; 241: 2035–2038.
3. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? *Lancet* 1997; 350(Suppl 1): S14–9.
4. Misko J. Evaluation of myocardial perfusion and viability in coronary artery disease in view of the new revascularization guidelines. *Nuclear Med Rev Central Eur Eur* 2012; 15: 46–51.
5. Martin JF, Shaw T, Heggie J, Penington DG. Measurement of the density of human platelets and its relationship to volume. *Br J Haematol* 1983; 54: 337–352.
6. Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. *Acta Haematol* 1999; 101: 140–144.
7. Zuberi BF, Akhtar N, Afsar S. Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. *Singapore Med J* 2008; 49: 114–116.
8. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002; 105: 539–542.
9. Ficaro EP, Lee BC, Kritzman JN, Corbett JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology. *J Nucl Cardiol* 2007; 14: 455–465.
10. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. *Rev Diabet Studies* 2012; 9: 6–22.
11. Bae SH, Lee J, Roh KH, Kim J. Platelet activation in patients with diabetic retinopathy. *Korean J Ophthalmol* 2003; 17: 140–144.

12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001; 414: 813–820.

13. Kitada S, Otsuka Y, Kokubu N, et al. Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. *Cardiovasc Diabetol* 2010; 9: 75.

14. Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N. Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. *Cardiovasc Diabetol* 2011; 10: 58.

15. Morrish NJ, Wang SL, Stevens LK, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetics. *Diabetologia* 2001; 44(Suppl 2): S14–21.

16. Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. *Br Med J* 1990; 301: 92–95.

17. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in non-insulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. *Am J Cardiol* 1997; 79: 134–139.

18. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. *J Diabetes Complicat* 2009; 23: 89–94.

19. Senaran H, Ileri M, Altinbas A, et al. Thrombopoietin and mean platelet volume in patients with metabolic syndrome and its relationship with insulin resistance in non-obese, non-diabetic patients. *Clin Cardiol* 2005; 28: 405–408.

20. Thomas GS, Miyamoto MI, Morello AP, 3rd, et al. Technetium 99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting. The Nuclear Utility in the Community (NUC) Study. *J Am Coll Cardiol* 2004; 43: 213–223.

21. Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Impairment of coronary microvascular dilation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. *Diabetes* 2001; 50: 1180–1185.

22. Djaheri R, Beishuizen ED, Pereira AM, et al. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. *Diabetologia* 2008; 51: 1581–1593.

23. Endler G, Klimesch A, Sunder-Plasmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. *Br J Haematol* 2002; 117: 399–404.

24. Coppinger JA, Carney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. *Blood* 2004; 103: 2096–2104.

25. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. *J Clin Investig* 2005; 115: 3378–3384.

26. Rao AK, Goldberg RE, Walsh PN. Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. *J Lab Clin Med* 1984; 103: 82–92.

27. Jakubowksi JA, Adler B, Thompson CB, Valeri CR, Deykin D. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. *J Lab Clin Med* 1985; 105: 271–276.

28. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. *Thrombolysis in Myocardial Infarction* 2001; 51: 634–639.

29. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. *New Engl J Med* 1999; 332: 1549–1554.

30. Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. *Thromb Res* 2007; 120: 245–250.

31. Varol E, Akcay S, Ozaydin M, Erdogan D, Dogan A, Altinbas A. Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease. *J Cardiol* 2010; 56: 154–158.

32. Coban E, Bostan F, Ozdogan M. The mean platelet volume in subjects with impaired fasting glucose. *Platelets* 2006; 17: 67–69.

33. Cay S, Biyikoglu F, Cihan G, Korkmaz S. Mean platelet volume in the patients with cardiac syndrome X. *J Thromb thrombol* 2005; 20: 175–178.

34. Gokce M, Kaplan S, Tekelioğlu Y, Erdogan T, Kucukosmanoğlu M. Platelet function disorder in patients with coronary slow flow. *Clin Cardiol* 2005; 28: 145–148.